A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials First published 28/09/2021 Last updated 30/10/2024 EU PAS number:EUPAS43115 Study Finalised